These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
258 related articles for article (PubMed ID: 21963050)
21. [Clinical impact of body mass index on prostate biopsy in patients with intermediate PSA levels]. Sekita N; Suzuki H; Kamijima S; Chini K; Fujimura M; Mikami K Hinyokika Kiyo; 2008 Jul; 54(7):479-83. PubMed ID: 18697492 [TBL] [Abstract][Full Text] [Related]
22. The impact of hypertriglyceridemia on prostate cancer development in patients aged ≥60 years. Hayashi N; Matsushima M; Yamamoto T; Sasaki H; Takahashi H; Egawa S BJU Int; 2012 Feb; 109(4):515-9. PubMed ID: 21812901 [TBL] [Abstract][Full Text] [Related]
23. Impact of obesity on the utility of preoperative prostate-specific antigen velocity to predict for relapse after prostatectomy: a report from the SEARCH database. King CR; Freedland SJ; Terris MK; Kane CJ; Amling CL; Aronson WJ; Presti JC Urology; 2007 May; 69(5):921-6. PubMed ID: 17482935 [TBL] [Abstract][Full Text] [Related]
24. Obesity and screening PSA levels among men undergoing an annual physical exam. Rundle A; Neugut AI Prostate; 2008 Mar; 68(4):373-80. PubMed ID: 18189231 [TBL] [Abstract][Full Text] [Related]
25. Prostate cancers diagnosed at repeat biopsy are smaller and less likely to be high grade. Tan N; Lane BR; Li J; Moussa AS; Soriano M; Jones JS J Urol; 2008 Oct; 180(4):1325-9; discussion 1329. PubMed ID: 18707706 [TBL] [Abstract][Full Text] [Related]
26. Body mass index and prostate-specific antigen failure following brachytherapy for localized prostate cancer. Efstathiou JA; Skowronski RY; Coen JJ; Grocela JA; Hirsch AE; Zietman AL Int J Radiat Oncol Biol Phys; 2008 Aug; 71(5):1302-8. PubMed ID: 18262732 [TBL] [Abstract][Full Text] [Related]
27. Histological diagnosis of prostate cancer in Korean men aged 70-79 years. Shim HB; Lee SE; Park HK; Ku JH Jpn J Clin Oncol; 2007 Oct; 37(10):782-7. PubMed ID: 17913831 [TBL] [Abstract][Full Text] [Related]
28. Association between low serum free testosterone and adverse prognostic factors in men diagnosed with prostate cancer in KwaZulu-Natal. Alsharef MM; Kahie A; Conradie M; Goad EA; Fourie T S Afr J Surg; 2012 Mar; 50(2):40-2. PubMed ID: 22622101 [TBL] [Abstract][Full Text] [Related]
29. Investigative clinical study on prostate cancer part VI: Follicle-stimulating hormone and the pituitary-testicular-prostate axis at the time of initial diagnosis and subsequent cluster selection of the patient population. Porcaro AB; Migliorini F; Petrozziello A; Sava T; Romano M; Caruso B; Cocco C; Ghimenton C; Zecchinini Antoniolli S; Lacola V; Rubilotta E; Monaco C; Comunale L Urol Int; 2012; 88(2):150-7. PubMed ID: 22205171 [TBL] [Abstract][Full Text] [Related]
30. Obesity and prostate enlargement in men with localized prostate cancer. Kopp RP; Han M; Partin AW; Humphreys E; Freedland SJ; Parsons JK BJU Int; 2011 Dec; 108(11):1750-5. PubMed ID: 21736693 [TBL] [Abstract][Full Text] [Related]
31. Prostate-specific antigen velocity and the detection of gleason score 7 to 10 prostate cancer. Punglia RS; Cullen J; McLeod DG; Chen Y; D'Amico AV Cancer; 2007 Nov; 110(9):1973-8. PubMed ID: 17886252 [TBL] [Abstract][Full Text] [Related]
32. [Staging of prostate cancer: value of the combined information of endorectal MRI, biopsy Gleason score, and preoperative PSA level]. Wetter A; Ajdukovic AN; Fliessbach K; Lehnert T; Engl T; Jacobi V; Vogl TJ Rofo; 2006 Apr; 178(4):385-90. PubMed ID: 16607587 [TBL] [Abstract][Full Text] [Related]
33. Prostate-specific antigen velocity at low prostate-specific antigen levels as screening tool for prostate cancer: results of second screening round of ERSPC (ROTTERDAM). Roobol MJ; Kranse R; de Koning HJ; Schröder FH Urology; 2004 Feb; 63(2):309-13; discussion 313-5. PubMed ID: 14972478 [TBL] [Abstract][Full Text] [Related]
34. Obesity does not correlate with adverse pathologic findings on transperineal template-guided mapping biopsy of the prostate. Bittner N; Merrick GS; Stewart R; Andreini H; Taubenslag W; Curtis R; Butler WM; Wallner KE Urol Oncol; 2011; 29(4):398-404. PubMed ID: 19945303 [TBL] [Abstract][Full Text] [Related]
35. Obesity-PSA relationship: a new formula. Hekal IA; Ibrahiem EI Prostate Cancer Prostatic Dis; 2010 Jun; 13(2):186-90. PubMed ID: 20029402 [TBL] [Abstract][Full Text] [Related]
36. The association of diabetes mellitus and high-grade prostate cancer in a multiethnic biopsy series. Moreira DM; Anderson T; Gerber L; Thomas JA; Bañez LL; McKeever MG; Hoyo C; Grant D; Jayachandran J; Freedland SJ Cancer Causes Control; 2011 Jul; 22(7):977-83. PubMed ID: 21562753 [TBL] [Abstract][Full Text] [Related]
37. Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter. Thompson IM; Pauler DK; Goodman PJ; Tangen CM; Lucia MS; Parnes HL; Minasian LM; Ford LG; Lippman SM; Crawford ED; Crowley JJ; Coltman CA N Engl J Med; 2004 May; 350(22):2239-46. PubMed ID: 15163773 [TBL] [Abstract][Full Text] [Related]
38. Impact of diabetes mellitus on the detection of prostate cancer via contemporary multi (≥ 12)-core prostate biopsy. Hong SK; Oh JJ; Byun SS; Hwang SI; Lee HJ; Choe G; Lee SE Prostate; 2012 Jan; 72(1):51-7. PubMed ID: 21520162 [TBL] [Abstract][Full Text] [Related]
39. Impact of positive surgical margins on prostate-specific antigen failure after radical prostatectomy in adjuvant treatment-naïve patients. Ploussard G; Agamy MA; Alenda O; Allory Y; Mouracade P; Vordos D; Hoznek A; Abbou CC; de la Taille A; Salomon L BJU Int; 2011 Jun; 107(11):1748-54. PubMed ID: 20883488 [TBL] [Abstract][Full Text] [Related]
40. Obesity, serum prostate specific antigen and prostate size: implications for prostate cancer detection. Freedland SJ; Platz EA; Presti JC; Aronson WJ; Amling CL; Kane CJ; Terris MK J Urol; 2006 Feb; 175(2):500-4; discussion 504. PubMed ID: 16406980 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]